thalidomide has been researched along with Acquired Autoimmune Hemolytic Anemia in 9 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The diagnosis of multiple myeloma and Evan's syndrome was made, we underwent chemotherapy by BTD (bortezomib-thalidomide-dexamethasone) and continuous corticosteroid therapy but unfortunately the patient died secondary of a Lactic acidosis." | 3.83 | Multiple myeloma associated with an Evan's syndrome. ( Abderrahim, K; Amina, BB; Asma, A; Bechir, A; Emna, B; Haifa, R; Mondher, K; Mrabet, S; Nesrine, BS; Senda, M; Yosra, BY, 2016) |
| "One patient developed autoimmune hemolytic anemia and another grade 4 thrombocytopenia." | 2.87 | Lenalidomide as immune adjuvant to a dendritic cell vaccine in chronic lymphocytic leukemia patients. ( Adamson, L; Eriksson, I; Gentilcore, G; Hansson, L; Heimersson, K; Mellstedt, H; Mozaffari, F; Mulder, TA; Näsman-Glaser, B; Österborg, A; Palma, M; Ryblom, H; Svensson, A, 2018) |
| "Lenalidomide is an amino-substituted analog of thalidomide with potent immunomodulatory properties." | 1.38 | Plasma exchange and rituximab treatment for lenalidomide-associated cold agglutinin disease. ( Akpek, G; Brauer, DL; Edelman, B; Hess, JR; Rapoport, AP, 2012) |
| "Autoimmune haemolytic anaemia is also recognised, is frequently difficult to treat and overall prognosis is often poor, usually from associated problems." | 1.31 | Remission of severe, intractable autoimmune haemolytic anaemia following matched unrelated donor transplantation. ( Kinsey, SE; Pratt, G, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Wu, Y | 1 |
| Yang, K | 1 |
| Kong, W | 1 |
| Xiao, J | 1 |
| Liu, X | 1 |
| Palma, M | 1 |
| Hansson, L | 1 |
| Mulder, TA | 1 |
| Adamson, L | 1 |
| Näsman-Glaser, B | 1 |
| Eriksson, I | 1 |
| Heimersson, K | 1 |
| Ryblom, H | 1 |
| Mozaffari, F | 1 |
| Svensson, A | 1 |
| Gentilcore, G | 1 |
| Österborg, A | 1 |
| Mellstedt, H | 1 |
| Fattizzo, B | 1 |
| Zaninoni, A | 1 |
| Nesa, F | 1 |
| Sciumbata, VM | 1 |
| Zanella, A | 1 |
| Cortelezzi, A | 1 |
| Barcellini, W | 1 |
| Chic Acevedo, C | 1 |
| García Torres, E | 1 |
| Álvarez Rivas, MÁ | 1 |
| Bechir, A | 1 |
| Haifa, R | 1 |
| Nesrine, BS | 1 |
| Emna, B | 1 |
| Senda, M | 1 |
| Asma, A | 1 |
| Amina, BB | 1 |
| Mrabet, S | 1 |
| Yosra, BY | 1 |
| Mondher, K | 1 |
| Abderrahim, K | 1 |
| Sun, WL | 1 |
| Köck, L | 1 |
| Walder, A | 1 |
| Erdel, M | 1 |
| Kilga-Nogler, S | 1 |
| Schennach, H | 1 |
| Fiegl, M | 1 |
| Brauer, DL | 1 |
| Edelman, B | 1 |
| Rapoport, AP | 1 |
| Hess, JR | 1 |
| Akpek, G | 1 |
| Darabi, K | 1 |
| Kantamnei, S | 1 |
| Wiernik, PH | 1 |
| Pratt, G | 1 |
| Kinsey, SE | 1 |
1 trial available for thalidomide and Acquired Autoimmune Hemolytic Anemia
| Article | Year |
|---|---|
Lenalidomide as immune adjuvant to a dendritic cell vaccine in chronic lymphocytic leukemia patients.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; A | 2018 |
8 other studies available for thalidomide and Acquired Autoimmune Hemolytic Anemia
| Article | Year |
|---|---|
Thalidomide-associated autoimmune hemolytic anemia.
Topics: Anemia, Hemolytic; Anemia, Hemolytic, Autoimmune; Humans; Thalidomide | 2023 |
Lessons from very severe, refractory, and fatal primary autoimmune hemolytic anemias.
Topics: Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Murine-Derived; Erythrocytes; Hemolysis; Huma | 2015 |
[Cold agglutinin disease of IgA class as early manifestation of multiple myeloma and resolution after treatment with new anti-myeloma drugs].
Topics: Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols | 2016 |
Multiple myeloma associated with an Evan's syndrome.
Topics: Acidosis, Lactic; Adrenal Cortex Hormones; Anemia, Hemolytic, Autoimmune; Antineoplastic Combined Ch | 2016 |
Successful treatment of MDS with lenalidomide, complicated by transient autoimmune hemolysis.
Topics: Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Female; Humans; Immunoglobulins; Lenalidomide; | 2010 |
Plasma exchange and rituximab treatment for lenalidomide-associated cold agglutinin disease.
Topics: Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Combin | 2012 |
Lenalidomide-induced warm autoimmune hemolytic anemia.
Topics: Aged; Anemia, Hemolytic, Autoimmune; Female; Humans; Lenalidomide; Lymphoma, B-Cell; Thalidomide | 2006 |
Remission of severe, intractable autoimmune haemolytic anaemia following matched unrelated donor transplantation.
Topics: Adrenal Cortex Hormones; Alemtuzumab; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal; Antibod | 2001 |